BioVaxys Technology Corp. (BVAXF) Stock

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company primarily engaged in the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Its product pipeline features several key candidates, including two SARS-CoV-2 vaccines: BVX-0320, a monovalent version, and BVX-0121, a multivalent option. In the oncology space, BioVaxys is advancing BVX-0918A, a haptenized tumor cell vaccine designed for ovarian cancer, and BVX-0918C, aimed at cervical cancer. The company also has programs addressing Human Papillomavirus (HPV), such as Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, BioVaxys offers CoviDTH, an immunodiagnostic tool developed to detect immune system responses in individuals previously exposed to SARS-CoV-2. To support its development initiatives, BioVaxys has established several strategic collaborations. It holds a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, crucial components for BVX-0320 and CoviDTH. The company also has a research collaboration for BVX-0320 with The Ohio State University, Wexner School of Medicine. Additionally, Bioanalytical Systems, Inc. is conducting preclinical toxicology studies for BioVaxys' CoviDTH immunodiagnostic under a separate agreement. The company's operations are headquartered in Vancouver, Canada.

BioVaxys Technology Corp. is headquartered in CA.

BioVaxys Technology Corp. (BVAXF) stock trades at $0.11 with a market capitalization of $3.27M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.59, reflecting a net loss over the last twelve months, a negative price-to-book of -0.56, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.02 and $0.27, and currently trades 59.3% below its 52-week high.

On profitability, BioVaxys Technology Corp. generates a return on equity (ROE) of 121.88% (not meaningful, as shareholders' equity is negative), return on capital employed of 92.14%.

Official website: www.biovaxys.com